--- title: "What did Purdue make and own, and with whom did it deal?" language: en canonical: https://dossiertwist.com/dossiers/purdue-pharma/business-and-products/ as_of: 2026-10-22 keywords: ["Purdue Pharma L.P.","Purdue Pharma Inc.","OxyContin","Sackler family","Richard Sackler","Pharmaceutical Research Associates L.P.","Beacon Company","Rosebay Medical Company L.P.","The Purdue Frederick Company","Rhodes Pharmaceuticals","Chapter 11","Harrington v. Purdue Pharma L.P.","third-party releases","Knoa Pharma","McKinsey & Company","opioid litigation","guilty plea","Master Disbursement Trust","shareholder settlement","Mundipharma"] --- # What did Purdue make and own, and with whom did it deal? **Question.** What did Purdue Pharma L.P. own and sell, how much did OxyContin earn, and which companies did it deal with? **Answer.** Purdue Pharma L.P. was the operating partnership of a group that sold branded medicines, above all OxyContin, and through the Rhodes companies generic ones. The District Court put its revenue for 1996–2019 at about $34 billion, mostly from OxyContin, a figure the Supreme Court quoted; other speakers give other totals. It made OxyContin and Hysingla itself, had a plant built in Durham, North Carolina, invested in biotechnology companies, litigated and settled patent cases and, during the bankruptcy, sold the Rhodes Technologies ingredient plant in Coventry, Rhode Island, and its consumer health business. A campaign-finance research organisation reported its 2017–2018 spending on congressional lobbying, and a political committee registered with the FEC under Purdue Pharma Inc.'s name in 2001 is listed there as terminated. ## The group and its two businesses - Analysis: According to the debtors' July 2025 Disclosure Statement, Purdue Pharma L.P., a Delaware limited partnership based in Stamford, Connecticut, with Purdue Pharma Inc. as general partner, was the main operating entity of a group with two businesses: branded prescription medicines, opioid and non-opioid, carried on mainly by Purdue Pharma L.P. and its subsidiaries other than the Rhodes companies, and generic medicines developed and distributed by Rhodes Associates L.P. and its subsidiaries. Its petition of 15 September 2019 states that it directly owned 100% of Purdue Transdermal Technologies L.P., Purdue Pharmaceuticals L.P., Purdue Pharma Manufacturing L.P., Adlon Therapeutics L.P., Imbrium Therapeutics L.P., Greenfield BioVentures L.P., Nayatt Cove Lifescience Inc., Purdue Pharmaceutical Products L.P., Rhodes Associates L.P., Avrio Health L.P., Seven Seas Hill Corp. and Ophir Green Corp., and 99% of Purdue Neuroscience Company, whose other 1% Purdue Pharma Inc. held; Rhodes Associates L.P. owned Rhodes Technologies, Rhodes Pharmaceuticals L.P. and Paul Land Inc., and Rhodes Technologies owned UDF L.P. and SVC Pharma Inc. The debtors count 22 operating and non-operating subsidiaries in the United States and the British Virgin Islands; most of the debtors are managed by a single board and wholly owned by the same ultimate owners, trusts for the descendants of Mortimer and Raymond Sackler. By July 2025 the debtors employed about 439 people, about 40% fewer than at the petition and 76% fewer than in 2017 (the sale of the Coventry ingredients plant alone reduced headcount by about 120, many of whom received offers from the buyer), and had no funded debt, no material past-due trade debt and no judgment creditors. [src-015] [src-001] ## Products - Analysis: In the early 1980s Purdue developed its first controlled-release morphine drug, marketed as MS Contin, the District Court recorded. Its three principal branded opioids were OxyContin, an extended-release oxycodone tablet approved by the FDA in 1995 and launched in 1996, whose abuse-deterrent reformulation was approved and launched in 2010; Hysingla ER, an abuse-deterrent extended-release hydrocodone tablet approved in 2014 and launched in 2015; and Butrans, a seven-day buprenorphine patch approved in 2010 and launched in 2011. The Purdue debtors made OxyContin and Hysingla themselves and, in limited amounts, OxyContin for foreign independent associated companies ultimately owned by the Sackler families, which paid Purdue Pharma L.P. royalties on sales outside the United States; Butrans was made by a third party, LTS Lohmann Therapie-Systeme AG. A 2018 patent settlement lists the 'Purdue Products' as OxyContin, Butrans, Hysingla ER, Intermezzo, Senokot, Colace, Betadine, SlowMag, Symproic, Dilaudid and MS Contin. [src-003] [src-015] [src-010] - Analysis: Company announcements describe later non-opioid work. A June 2017 announcement by the board of the Purdue/Napp/Mundipharma network, appointing Craig Landau chief executive of Purdue Pharma L.P., credited the departing Mark Timney, in office since 2014, with a collaboration with AnaBios on non-opioid pain compounds, the purchase of VM-902A and the TrkA pain program from VM Pharma, a $790 million research collaboration with Exicure on psoriasis, a collaboration with Eisai on lemborexant and an alliance with Shionogi to launch Symproic (naldemedine) in the United States; the agreements themselves are not in the record. A March 2019 press report of company announcements said the FDA had approved Adhansia XR, an extended-release methylphenidate capsule for attention deficit hyperactivity disorder in patients aged six and older, made by the new subsidiary Adlon Therapeutics, whose general manager Marcelo Bigal was also Purdue's chief medical officer, shortly after another subsidiary, Imbrium Therapeutics, received an orphan drug designation for a bile-duct cancer treatment; both were based in Purdue's building at 201 Tresser Boulevard, Stamford. [src-074] [src-050] ## How much OxyContin earned - Analysis: OxyContin provided most of the revenue. The District Court's December 2021 decision records that by 2001 annual OxyContin sales had reached $1 billion, bonuses to sales representatives for OxyContin had grown from $1 million in 1996 to $40 million, and the drug was the most prescribed brand-name narcotic in the United States. It put Purdue's revenue for 1996–2019 at about $34 billion, mostly from OxyContin sales, a total the Supreme Court quoted in 2024, and stated that before the bankruptcy OxyContin made up some 91% of Purdue's U.S. revenue. An IRS special agent's sworn 2007 declaration supporting the forfeiture complaint against The Purdue Frederick Company states that the FDA approved OxyContin on 12 December 1995, that its sales were booked by The Purdue Pharma Company until that partnership ended on 30 September 2004 and then by Purdue Pharma L.P., of which Purdue Frederick then became an owner, and that gross OxyContin sales from 1995 to June 2006 were about $10.2 billion, or $8.4 billion net of rebates and discounts. A 2010 WIPO panel decision recites, from Purdue's own submission in an uncontested domain-name case that the panel did not test, that OxyContin was the eighth best-selling U.S. drug, with sales of over $3 billion in 2009. [src-003] [src-040] [src-105] [src-036] - Analysis: Other speakers gave larger or narrower totals. The majority staff of the House Committee on Oversight and Reform wrote in December 2020, citing outside sources, that Purdue had generated more than $30 billion in OxyContin sales since 1996 and that the family had withdrawn more than $10 billion; this is a staff statement, not a finding of the committee. Connecticut's Attorney General alleged in 2019, from public information, revenue of about $3 billion a year, more than $35 billion since OxyContin's 1995 release and a June 2010 ten-year plan under which the Sacklers stood to receive at least $700 million a year through 2020, and Rhode Island's Attorney General alleged in 2022 that annual OxyContin sales had ranged from $2 billion to $3 billion since 2009; these unaudited pleading figures differ from the court's $34 billion. In Addendum A to its 2020 settlement with four family members and an estate the United States contended that Purdue's 2010–2018 profits were almost entirely driven by OxyContin, that an 11 April 2012 budget presentation to the board showed federal health programs providing over 30% of OxyContin revenue, and that a presentation by the chief financial officer to the board around 20 June 2011 cut the OxyContin sales forecast from $3.9 billion to $2.8 billion after the reformulation. The agreement admits no liability and concedes nothing for the United States, the five expressly deny the allegations, and they agreed to pay the United States $225,000,000 plus interest. [src-037] [src-051] [src-055] [src-004] [src-003] ## Plants, research sites and property - Analysis: Production and research sites moved over time. The federal Information filed against Purdue Pharma L.P. in New Jersey on 24 November 2020 states as background that it ran a non-clinical research facility in Cranbury from about February 2002 to July 2017 and leased a smaller one in Princeton from about March 2017 to September 2019, and that from at least 2002 through the first half of 2015 it sold OxyContin tablets made by The P.F. Laboratories Inc. at Totowa, with overflow offices in West Paterson from about 2005 to 2010. These are background statements in a charging document about facilities rather than conduct; the District Court records that Purdue pleaded guilty to that Information in November 2020. [src-041] [src-003] - Analysis: For oral solid doses Purdue Pharma Manufacturing L.P. built a new plant in Durham, North Carolina. KBR announced on 9 July 2014 that its subsidiary KBR Building Group had won the contract for the 188,000-square-foot plant on a 51-acre site in Treyburn Corporate Park, having done construction work for Purdue Pharma Manufacturing before; the contractor's release states no contract value. A construction-industry award listing of 1 November 2016 names Purdue Pharma Manufacturing LP as owner of the two-storey plant, with floors of 128,000 and 60,000 square feet and about 46,000 square feet of offices and laboratories, SSOE Inc. as lead designer and engineer, McKee Building Group as program manager and BE&K Building Group, not KBR Building Group, as general contractor; the trade account does not explain the difference between the two contractors. [src-063] [src-082] - Analysis: Rhodes Technologies ran an ingredients plant on Washington Street in Coventry, Rhode Island, which a Rhode Island permit notice of 25 March 2015 describes as making active pharmaceutical ingredients for finished-dose medicines and which originally made oxycodone for OxyContin. The debtors chose to outsource these ingredients and, during the bankruptcy, sold the plant. A 2021 student case study, drawing on the sale motion and order, which are not themselves in the record, reports a competitive sale to Noramco Coventry LLC on condition of a supply agreement of at least seven years with two two-year renewals at the debtors' option, approved without any objection being filed. The debtors' Disclosure Statement records the asset purchase agreement of 14 September 2020 between Rhodes Technologies, Noramco Coventry LLC as buyer and Noramco LLC as guarantor, the Bankruptcy Court's order of 1 October 2020 approving the sale and a supply agreement with Noramco LLC, and closing on 31 December 2020. [src-079] [src-059] [src-015] - Analysis: In New York, Purdue Pharma L.P. and Millsaw Realty L.P. filed parallel protest petitions in October and November 2004 against the rezoning of a 7.45-acre parcel on Route 9A in Hastings-on-Hudson sought by the developer Saw Mill Lofts, LLC. Because the petitions required a 4-1 majority, the local law on which the village board voted 3-2 on 5 October 2004 was not filed until the board announced on 27 September 2005 that both had unconditionally withdrawn them. [src-072] ## The Rhodes generic companies - Analysis: The Rhodes generic companies were not always Purdue subsidiaries. According to the debtors' 2025 Disclosure Statement, Rhodes Tech (or its predecessor) was a Purdue Pharma L.P. subsidiary until, on or around 1 January 2008, Purdue distributed its interest in Rhodes Tech's parent to an affiliate, moving it into another Sackler ownership chain with the same ultimate owners, alongside Rhodes Pharma, created in 2008. The two had their own boards until May 2019, although some of their directors were also Purdue directors or officers, and in May 2019 they were contributed to Purdue Pharma L.P. From 2017, the same document states, Rhodes Pharma sold the MS Contin and Dilaudid brands contributed to it by Purdue and an authorized generic of Butrans under a profit share. [src-015] - Analysis: State complaints describe other structures. New York's Attorney General alleged in a complaint filed in Suffolk County on 13 September 2019 that the Sacklers formed Rhodes while Purdue was under federal investigation; that Rhodes Pharmaceuticals L.P. and Rhodes Technologies were each wholly owned by Coventry Technologies L.P. and ultimately by trusts for the family, with Rhodes Pharmaceuticals Inc. and Rhodes Technologies Inc. as their general partners; that a former senior manager called Rhodes a 2007 'landing pad' for the family; and that Rhodes began selling generic opioids in 2009. Rhode Island's Attorney General alleged in March 2022 that Rhodes Technologies Inc., general partner of Rhodes Technologies, was a subsidiary of Purdue Pharma L.P.; that Coventry Technologies L.P., whose general partner is Purdue Pharma Inc., was the sole limited partner of Rhodes Pharmaceuticals L.P.; and that Rhodes made authorized generics of OxyContin and Butrans and the active ingredient of OxyContin. These are pleadings. The New York structure matches the separate chain the debtors place between 2008 and May 2019 rather than the one in the petition; the Rhode Island account describes the structure as pleaded in 2022, and the United States lists Coventry Technologies equity among the assets Purdue moved to its parent with an estimated date of 1 January 2008. The debtors' account is that Rhodes Tech left Purdue around 1 January 2008, came under common ownership with Rhodes Pharma, created that year, and that both were contributed to Purdue Pharma L.P. in May 2019; at the 15 September 2019 petition Rhodes Associates L.P., wholly owned by Purdue Pharma L.P., directly owned 100% of Rhodes Technologies and Rhodes Pharmaceuticals L.P. [src-014] [src-015] [src-001] [src-055] [src-038] - Analysis: Rhodes Technologies Inc. also appears as a creditor: Purdue Pharma L.P.'s list of its 50 largest unsecured creditors filed with the September 2019 petition includes it, at 201 Tresser Boulevard, Stamford, for services fees that the scanned list renders as '51,034,782', most likely $1,034,782; the amount rests on an optical transcription of the scan. [src-001] ## Investments and alliances - Analysis: In November 2008 Purdue Pharmaceutical Products L.P., acting through its general partner Purdue Pharmaceutical Products Inc. and that company's senior vice president for licensing and business development, James J. Dolan, formed an alliance with Infinity Pharmaceuticals, Inc., effective 19 November 2008, to develop and sell FAAH products in the United States. Infinity's announcement of 20 November added Mundipharma International Corporation Limited as partner for oncology products outside the United States and said that 'Purdue' had bought four million Infinity shares for $45 million at $11.25 each, that the partners would invest a further $30 million in shares and warrants and that Purdue would provide a $50 million credit line. The announcement does not say which Purdue entity invested. Richard Sackler, a director of Purdue Pharma Inc. until 24 July 2018, stated in a March 2019 declaration supporting his motion to dismiss the Massachusetts Attorney General's complaint that Purdue Pharma L.P. had an investment in Infinity that ended in about 2013 and entered into a securities purchase agreement with Novelos Therapeutics in 2009, describing Infinity as a cancer-treatment company and Novelos as a developer of cancer and hepatitis treatments, neither involved with opioids; his account is consistent in part with the companies' SEC filings, and the United States lists Infinity stock among assets Purdue transferred to its parent PRA LP. [src-024] [src-007] - Analysis: Novelos Therapeutics' 2010 prospectus records that investment: on 11 February 2009 Novelos sold Purdue Pharma, L.P., which it described as an independent associated company of Mundipharma, 200 Series E preferred shares with warrants for up to 9,230,769 common shares at $0.65 for $10,000,000 (about $9,200,000 net), alongside a collaboration agreement with Mundipharma, and after further financings on 25 August and 10 November 2009 Purdue transferred its Novelos preferred stock, common stock and warrants to Beacon Company and Rosebay Medical Company L.P. The United States instead lists Novelos stock valued at $23,140,097 as moved to PRA LP on 28 February 2009; the two records name different recipients and are not reconciled. [src-025] ## Patents, trademarks and settlements - Analysis: Purdue litigated its OxyContin patents. A settlement agreement of 28 August 2006 records that Purdue Pharma L.P. (on its own behalf and as successor to The Purdue Pharma Company), The Purdue Frederick Company Inc., The P.F. Laboratories, Inc. and Euro-Celtique S.A. owned U.S. patents 5,549,912, 5,508,042 and 5,656,295 on controlled-release oxycodone including OxyContin, and ended their litigation in the Southern District of New York with Endo Pharmaceuticals Inc. and Endo Pharmaceuticals Holdings Inc. over Endo's application to sell generic OxyContin (ANDA No. 75-923). The Federal Circuit had vacated a judgment that the patents were unenforceable for inequitable conduct and affirmed that Endo infringed them; the parties settled with a consent judgment, a patent licence agreement and mutual releases. [src-046] - Analysis: Purdue also paid to settle. Under an agreement dated 28 August 2018, Purdue Pharma L.P., The P.F. Laboratories, Inc. and Purdue Pharmaceuticals L.P. ended Depomed, Inc. v. Purdue Pharma L.P. (D.N.J. No. 3:13-cv-00571) with Assertio Therapeutics, Inc., formerly Depomed, agreeing that one or more of them would pay $30 million on signing and $32 million by 1 February 2019 as a settlement of royalties for use of Assertio's patents, with no admission of liability, infringement or validity by either side. Jon Lowne signed as VP, CFO for both partnerships through their general partner Purdue Pharma, Inc., and Edward B. Mahony as VP, Finance for The P.F. Laboratories. [src-010] - Analysis: Purdue Pharma L.P. also defended its trademark. A WIPO Arbitration and Mediation Center decision of 4 December 2010 records that it is the registered owner of at least two OXYCONTIN marks, U.S. Registration No. 2004586 of 1996 and No. 2033914 of 1997, and orders four domain names containing 'oxycontin' transferred to it from an unaffiliated individual registrant who filed no substantive response. [src-036] ## Contractors and grants described under oath - Analysis: Two chief executives described business ties in sworn declarations supporting their motion to dismiss the Massachusetts Attorney General's complaint. Craig Landau, who stated that he had been chief executive since June 2017 and was earlier chief medical officer and head of clinical development, said that Purdue's agreements with the Massachusetts company Analgesic Research, which he signed in that role, concerned only the clinical development of Butrans and Hysingla, such as trial design, risk mitigation and materials for FDA applications, and not their marketing; he added that he did not negotiate the contracts or meet the company in Massachusetts and that other departments negotiated them. The agreements themselves are not in the record. John Stewart, chief executive from June 2007 to December 2013, stated that Purdue had to stop funding a Massachusetts General Hospital pain programme grant when it lost OxyContin patent protection and its revenue fell, and was asked to discuss resuming support once protection was restored; he said the Commonwealth's description of the grant as aimed at increasing opioid prescriptions did not match his understanding of its goal while he was chief executive. The available copy of his declaration is a spaced-out optical transcription. [src-011] [src-033] ## Businesses sold in the bankruptcy - Analysis: The debtors also sold their consumer business. A May 2023 press report states that Bankruptcy Judge Sean Lane, at a hearing in White Plains, approved the sale of Purdue's consumer health business, Avrio Health, which according to court documents sold over-the-counter antiseptics and laxatives and had never been involved in Purdue's opioid business, to a subsidiary of Arcadia Consumer Healthcare for $397 million; the report does not name the subsidiary, and the order and purchase agreement themselves are not in the record. The debtors' 2025 Disclosure Statement records an asset purchase agreement of 4 April 2023 for the sale of substantially all of Avrio's assets to Atlantis Consumer Healthcare Inc., a wholly owned subsidiary of Arcadia Consumer Healthcare, Inc., which guaranteed Atlantis's obligations; the Bankruptcy Court's order approving the sale, entered on 30 May 2023; and closing on 1 June 2023. It says that Avrio Health L.P. is now known as Purdue Products, L.P. [src-015] [src-048] ## Lobbying and the corporate PAC - Analysis: Official records and a research report describe Purdue's political activity. Federal Election Commission records show the PURDUE PHARMA INC. POLITICAL ACTION COMMITTEE (PURDUE PAC), committee C00370643, registered on 17 December 2001 as a qualified corporation PAC and lobbyist/registrant PAC; from 1 January to 16 September 2019 its cash fell from $43,894.25 to nil, with receipts of $2,750.32 and disbursements of $46,644.57, including $5,000 to other committees and four September payments of $10,000 to $10,500 to charities. An April 2019 report by a campaign-finance research organisation, compiled from federal lobbying and campaign-finance disclosures that are not in the record, states that Purdue Pharma's spending on congressional lobbying rose from $940,000 in 2017 to $1.12 million in 2018, that nine of its ten lobbyists in 2018 had previously worked in government and that the PAC gave almost only to Republican candidates, raising $35,679 and spending $20,733 in the 2018 cycle; the report calls it Purdue Pharma's PAC, while the FEC registers it under Purdue Pharma Inc.'s name. Craig Landau told the House Oversight Committee on 17 December 2020 that in the bankruptcy Purdue had agreed in a voluntary injunction to continue to refrain from lobbying for laws that might be read as encouraging opioid prescribing for pain, the New York Attorney General announced on 1 May 2026 that the successor, Knoa Pharma, will be barred from lobbying and advertising its opioid products, and the FEC lists the committee as terminated. [src-114] [src-095] [src-100] [src-005] ## Sources - [src-015] Court record source · src-015 - [src-001] Purdue's notice of suggestion of bankruptcy and automatic stay, with the Chapter 11 petition of Purdue Pharma L.P. (Commonwealth of Massachusetts v. Purdue Pharma L.P.), Commonwealth of Massachusetts (Office of the Attorney General), 2019-09-16 - [src-003] Memorandum decision and order of Judge Colleen McMahon vacating the confirmation order, In re Purdue Pharma L.P., S.D.N.Y. 21-cv-7532 (CM) (master case; filed as Document 148 in related case 7:21-cv-07585), Office of the Connecticut Attorney General, 2021-12-16 - [src-010] Settlement agreement between Purdue Pharma L.P. and affiliates and Depomed, Inc. (Exhibit 10.10), U.S. Securities and Exchange Commission (EDGAR), 2018-08-28 - [src-074] Company statement source · src-074 - [src-050] Media source · src-050 - [src-040] Harrington, United States Trustee, Region 2 v. Purdue Pharma L.P., No. 23-124, opinion of the Court and dissent, Supreme Court of the United States, 2024-06-27 - [src-105] Court record source · src-105 - [src-036] WIPO administrative panel decision, Case No. D2010-1811 (OxyContin domain names), WIPO Arbitration and Mediation Center, 2010-12-04 - [src-037] Majority staff memorandum, House Committee on Oversight and Reform, on the December 2020 hearing with Purdue and Sackler witnesses, U.S. House of Representatives, Committee on Oversight and Reform, 2020-12-08 - [src-051] Amended complaint, State of Connecticut v. Purdue Pharma L.P. et al., No. X07 HHD-CV-19-6105325-S (partially redacted), Office of the Connecticut Attorney General, 2019-05-06 - [src-055] Court record source · src-055 - [src-004] Settlement agreement between the United States and the Named Sacklers, with addenda, U.S. Department of Justice, 2020-10 - [src-041] Information, United States v. Purdue Pharma L.P., D.N.J. Criminal No. 20-1028 (MCA), U.S. Department of Justice, 2020-11-24 - [src-063] Company statement source · src-063 - [src-082] Media source · src-082 - [src-079] Rhode Island Pollutant Discharge Elimination System draft permit No. RI0023868 for Rhodes Technologies, Coventry (2015), U.S. Environmental Protection Agency (archived snapshot), 2015 - [src-059] Research source · src-059 - [src-072] Village of Hastings-on-Hudson notice: protest petitions for the Route 9A property withdrawn, Village of Hastings-on-Hudson, Board of Trustees, 2005 - [src-014] Court record source · src-014 - [src-038] Proof of claim of the United States (Department of Justice) in In re Purdue Pharma L.P., with attachment, Commonwealth of Massachusetts (Office of the Attorney General), 2020-07-30 - [src-024] Strategic Alliance Agreement between Infinity Pharmaceuticals, Inc. and Purdue Pharmaceutical Products L.P. (Exhibit 10.1), U.S. Securities and Exchange Commission (EDGAR), 2008-11-19 - [src-007] Declarations of the director defendants, Commonwealth of Massachusetts v. Purdue Pharma L.P., No. 1884-cv-01808(B), Commonwealth of Massachusetts (Office of the Attorney General), 2019-07-16 - [src-025] Novelos Therapeutics, Inc. prospectus (Rule 424(b)(3)), U.S. Securities and Exchange Commission (EDGAR), 2010 - [src-046] Settlement agreement between the Purdue companies and Endo Pharmaceuticals (Exhibit 99.1), U.S. Securities and Exchange Commission (EDGAR), 2006-08-28 - [src-011] Declaration of Craig Landau in support of the CEO defendants' motion to dismiss, Commonwealth of Massachusetts v. Purdue Pharma L.P., Commonwealth of Massachusetts (Office of the Attorney General), 2019-07-03 - [src-033] Declaration of John Stewart in support of the CEO defendants' motion to dismiss, Commonwealth of Massachusetts v. Purdue Pharma L.P., Commonwealth of Massachusetts (Office of the Attorney General), 2019-07-03 - [src-048] Media source · src-048 - [src-114] Federal Election Commission committee record: Purdue Pharma Inc. Political Action Committee (C00370643), U.S. Federal Election Commission - [src-095] Media source · src-095 - [src-100] Written testimony of Dr. Craig Landau, CEO of Purdue Pharma L.P., before the House Committee on Oversight and Reform, U.S. House of Representatives, Committee on Oversight and Reform, 2020-12-17 - [src-005] New York Attorney General press release on the shutdown of Purdue Pharma and the start of Knoa Pharma, Office of the New York State Attorney General, 2026-05-01